目标导向血小板输注可纠正血小板功能障碍并可能改善重型创伤性颅脑损伤患者生存
该回顾性研究纳入2015年7月至2016年10月单中心I级创伤中心成人重型TBI(头AIS≥3)且存在血小板功能障碍(血栓弹力图ADP抑制>60%)的患者35例,给予血小板输注,并与51例未输注的历史对照比较。输注后K时间缩短、α角、最大振幅和G值增加,ADP抑制得到纠正。输注组死亡率9% vs 对照组35%(p=0.005),逐步logistic回归显示血小板输注与死亡率降低独立相关(OR 0.23,95%CI 0.06-0.92,p=0.038)。作者结论认为血小板输注可纠正血小板抑制并可能降低死亡率。
要点
- 重型TBI(头AIS≥3)伴血小板功能障碍(TEG ADP抑制>60%)患者,输注血小板后ADP抑制得到纠正。
- 输注血小板后血栓弹力图显示K时间缩短、α角增大、最大振幅和G值升高,提示 clot strength 改善。
- 与51例历史对照相比,35例接受血小板输注者死亡率更低(9% vs 35%,p=0.005)。
- 逐步logistic回归显示血小板输注与死亡率降低独立相关(OR 0.23,95%CI 0.06-0.92,p=0.038)。
- 作者认为对重型TBI伴血小板功能障碍患者输注血小板可能改善生存,证据等级为治疗性II级。
适用人群与场景
- 成人创伤患者,来自单中心I级创伤中心,2015年7月至2016年10月入院。
- 纳入标准:重型TBI(头简明损伤定级AIS评分≥3)且存在血小板功能障碍(血栓弹力图ADP抑制>60%),并接受血小板输注。
- 历史对照组:重型TBI伴血小板功能障碍但未接受血小板输注的患者51例。
诊断标准与关键阈值
- 血小板功能障碍定义为血栓弹力图腺苷二磷酸(ADP)抑制大于60%。
- 重型TBI定义为头简明损伤定级(AIS)评分≥3。
研究设计与关键结果
- 研究类型:回顾性综述,单中心I级创伤中心,35例接受血小板输注的重型TBI伴血小板功能障碍患者与51例历史对照比较。
- 输注血小板后血栓弹力图参数改善:K时间缩短、α角增大、最大振幅增加、G值增加,ADP抑制得到纠正。
- 主要终点:输注组死亡率9% vs 历史对照组35%(p=0.005)。
- 逐步logistic回归:血小板输注与死亡率降低独立相关(OR 0.23,95%CI 0.06-0.92,p=0.038)。
证据类型、等级与局限
- 证据类型:回顾性综述(治疗性研究),证据等级II级。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于重型TBI(头AIS≥3)伴血小板功能障碍(TEG ADP抑制>60%)的成人患者,作者认为输注血小板可纠正血小板抑制并可能降低死亡率。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Platelet dysfunction, defined as adenosine diphosphate inhibition greater than 60% on thromboelastogram, is an independent predictor of increased mortality in patients with severe traumatic brain injury (TBI). We changed our practice to transfuse platelets for all patients with severe TBI and platelet dysfunction. We hypothesized that platelet transfusions would correct platelet dysfunction and improve mortality in patients with severe TBI.
METHODS: This retrospective review included adult trauma patients admitted to our Level I trauma center from July 2015 to October 2016 with severe TBI (head Abbreviated Injury Scale score ≥ 3) who presented with platelet dysfunction and subsequently received a platelet transfusion. Serial thromboelastograms were obtained to characterize the impact of platelet transfusion on clot strength. Subsequently, the platelet transfusion group was compared to a group of historical controls with severe TBI patients and platelet dysfunction who did not receive platelet transfusion.
RESULTS: A total of 35 patients with severe TBI presented with platelet dysfunction. Following platelet transfusion clot strength improved as represented by decreased K time, increased α angle, maximum amplitude, and G-value, as well as correction of adenosine diphosphate inhibition. When comparing to 51 historic controls with severe TBI and platelet dysfunction, the 35 study patients who received a platelet transfusion had a lower mortality (9% vs. 35%; p = 0.005). In stepwise logistic regression, platelet transfusion was independently associated with decreased mortality (odds ratio, 0.23; 95% confidence interval, 0.06-0.92; p = 0.038).
CONCLUSION: In patients with severe TBI and platelet dysfunction, platelet transfusions correct platelet inhibition and may be associated with decreased mortality.
LEVEL OF EVIDENCE: Therapeutic, level II.
参考来源
- Furay E, Daley M, Teixeira PG, et al. Goal-directed platelet transfusions correct platelet dysfunction and may improve survival in patients with severe traumatic brain injury. J Trauma Acute Care Surg. 2018. PMID: 30124626. doi:10.1097/TA.0000000000002047
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。